Literature DB >> 14593718

Cyclin-dependent kinase inhibitors.

Peter M Fischer1, Jane Endicott, Laurent Meijer.   

Abstract

Cyclin-dependent kinases are involved in diverse cellular processes that include cell cycle control, apoptosis, neuronal physiology, differentiation, and transcription. Intensive screening and drug design based on CDK/inhibitor co-crystal structures and on SAR studies have led to the identification and characterization of a large variety of chemical inhibitors of CDKs. Although they all act by competing with ATP for binding at the catalytic site of the kinase, their kinase selectivity varies greatly and remains to be studied in most cases. The requirement for CDKs in many physiological processes justifies their evaluation as potential therapeutic targets against a much larger scope of diseases than initially anticipated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14593718

Source DB:  PubMed          Journal:  Prog Cell Cycle Res        ISSN: 1087-2957


  17 in total

1.  Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis.

Authors:  Anna Santamaria; Rüdiger Neef; Uwe Eberspächer; Knut Eis; Manfred Husemann; Dominik Mumberg; Stefan Prechtl; Volker Schulze; Gerhard Siemeister; Lars Wortmann; Francis A Barr; Erich A Nigg
Journal:  Mol Biol Cell       Date:  2007-08-01       Impact factor: 4.138

Review 2.  Role of cell cycle proteins in CNS injury.

Authors:  Kimberly R Byrnes; Alan I Faden
Journal:  Neurochem Res       Date:  2007-04-03       Impact factor: 3.996

Review 3.  Spatial and temporal activation of spinal glial cells: role of gliopathy in central neuropathic pain following spinal cord injury in rats.

Authors:  Young S Gwak; Jonghoon Kang; Geda C Unabia; Claire E Hulsebosch
Journal:  Exp Neurol       Date:  2011-10-21       Impact factor: 5.330

4.  Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c.

Authors:  Satyajit K Karnik; Christina M Hughes; Xueying Gu; Orit Rozenblatt-Rosen; Graeme W McLean; Yue Xiong; Matthew Meyerson; Seung K Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-29       Impact factor: 11.205

5.  The mechanism of inhibition of the cyclin-dependent kinase-2 as revealed by the molecular dynamics study on the complex CDK2 with the peptide substrate HHASPRK.

Authors:  Iveta Bártová; Michal Otyepka; Zdenek Kríz; Jaroslav Koca
Journal:  Protein Sci       Date:  2005-01-04       Impact factor: 6.725

6.  The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.

Authors:  Jitka Holcakova; Peter Tomasec; Joachim J Bugert; Eddie Cy Wang; Gavin Wg Wilkinson; Roman Hrstka; Vladimir Krystof; Miroslav Strnad; Borivoj Vojtesek
Journal:  Antivir Chem Chemother       Date:  2010-01-05

7.  ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage.

Authors:  Yiping Huang; Tanusree Sen; Jatin Nagpal; Sunil Upadhyay; Barry Trink; Edward Ratovitski; David Sidransky
Journal:  Cell Cycle       Date:  2008-09-15       Impact factor: 4.534

8.  Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors.

Authors:  Prerna Diwan; Jonathan J Lacasse; Luis M Schang
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Functional flexibility of human cyclin-dependent kinase-2 and its evolutionary conservation.

Authors:  Iveta Bártová; Jaroslav Koca; Michal Otyepka
Journal:  Protein Sci       Date:  2007-11-27       Impact factor: 6.725

10.  Drug design with Cdc7 kinase: a potential novel cancer therapy target.

Authors:  Masaaki Sawa; Hisao Masai
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.